Patent · US Active

FGFR4 antibodies

US9284379B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

U3 Pharma GmbH · DE

Inventors

Johannes Bange · Planegg, DE
Jens Niewoehner · Munich, DE
Patricia Aus Dem Siepen · Feldafing, DE
Mike Rothe · San Mateo, US

Key dates

Filing date	Jan 18, 2013
Grant date	Mar 15, 2016
Priority date	—
Expiry date	Apr 4, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.